INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 43h ago
HOUSE PTR3h ago
SEC 13F3h ago
ROBINHOOD CHAIN3h ago
Corporate insider
HL

Hoch Lynelle

President, Cell Therapy Org.CIK 0002005382

EDGAR filingsOpen in network
Disclosed transactions14
Buys / sells0 / 0
Max Insider Score24
Connections1with evidence

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
13
HL
Hoch LynellePresident, Cell Therapy Org.
BMYBRISTOL MYERS SQUIBB CO
Option exercise
M—
838 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    BRISTOL MYERS SQUIBB COPresident, Cell Therapy Org. · Mar 12, 2026
12
HL
Hoch LynellePresident, Cell Therapy Org.
BMYBRISTOL MYERS SQUIBB CO
Other acquisition or disposition
J
—
94 sh
Mar 10, 2026
Mar 12, 2026
traded Mar 10, 2026
+2d
SEC FORM 4

Evidence

9
HL
Hoch LynellePresident, Cell Therapy Org.
BMYBRISTOL MYERS SQUIBB CO
Tax withholding
F$13K
212 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC FORM 4

Evidence

17
HL
Hoch LynellePresident, Cell Therapy Org.
BMYBRISTOL MYERS SQUIBB CO
Option exercise
M—
1,050 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC FORM 4

Evidence

12
HL
Hoch LynellePresident, Cell Therapy Org.
BMYBRISTOL MYERS SQUIBB CO
Other acquisition or disposition
J—
113 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC FORM 4

Evidence

9
HL
Hoch LynellePresident, Cell Therapy Org.
BMYBRISTOL MYERS SQUIBB CO
Tax withholding
F$16K
267 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC FORM 4

Evidence

21
HL
Hoch LynellePresident, Cell Therapy Org.
BMYBRISTOL MYERS SQUIBB CO
Option exercise
M—
6,304 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC FORM 4

Evidence

24
HL
Hoch LynellePresident, Cell Therapy Org.
BMYBRISTOL MYERS SQUIBB CO
Other acquisition or disposition
J—
3,095 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC FORM 4

Evidence

16
HL
Hoch LynellePresident, Cell Therapy Org.
BMYBRISTOL MYERS SQUIBB CO
Tax withholding
F$55K
912 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC FORM 4

Evidence

9
HL
Hoch LynellePresident, Cell Therapy Org.
BMYBRISTOL MYERS SQUIBB CO
Option exercise
M—
838 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC FORM 4

Evidence

21
HL
Hoch LynellePresident, Cell Therapy Org.
BMYBRISTOL MYERS SQUIBB CO
Option exercise
M—
1,050 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC FORM 4

Evidence

9
HL
Hoch LynellePresident, Cell Therapy Org.
BMYBRISTOL MYERS SQUIBB CO
Option exercise
M—
6,304 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC FORM 4

Evidence

9
HL
Hoch LynellePresident, Cell Therapy Org.
BMYBRISTOL MYERS SQUIBB CO
Grant or award
A—
6,531 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC FORM 4

Evidence

9
HL
Hoch LynellePresident, Cell Therapy Org.
BMYBRISTOL MYERS SQUIBB CO
Grant or award
A—
9,796 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC FORM 4

Evidence